The next generation in stent technology

STENTiT aims to redefine the landscape of endovascular treatments with the Resorbable Fibrillated Scaffold (RFS): a temporary vascular support structure capable of reconstructing the artery to provide better clinical outcomes.

Learn More

The Technology

Introducing the RFS

The Resorbable Fibrillated Scaffold (RFS) provides a temporary support structure to instantly restore blood flow and aims to facilitate a natural healing response to reconstruct the artery from the inside-out.

Learn More

First Clinical Application

Improve the treatment for CLTI

As a first target indication, we focus on reconstructing the artery for patients suffering from below-the-knee chronic limb-threatening ischemia (CLTI), a pressing issue affecting over 3.5 million patients across the EU and the US.

CLTI causes severe blood flow restriction to the foot, which can lead to amputation. The current standard of card, plain old balloon angioplasty (POBA), is highly ineffective, with re-occlusions occurring within 3 to 6 months.

Consequently, 250.000 amputations are still performed every year.

3.5M